Actinium Pharmaceuticals, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015. The unaudited interim statements are presented against Q1 2014 for operating results and cash flows, and December 31, 2014 for balance-sheet comparisons. Actinium is a clinical-stage biotechnology company developing radioimmunotherapy candidates; it had no approved products, commercial operations, or revenue.
Financial performance and liquidity
| Metric | Q1 2015 / March 31, 2015 | Comparable period / December 31, 2014 |
|---|---|---|
| Revenue | $0 | $0 in Q1 2014 |
| Research and development expense | $4.05 million | $1.59 million in Q1 2014 |
| General and administrative expense | $3.81 million | $2.55 million in Q1 2014 |
| Total operating expenses | $7.87 million | $4.14 million in Q1 2014 |
| Operating loss | $7.87 million | $4.14 million in Q1 2014 |
| Net loss | $3.07 million; $0.09 per share | $16.70 million; $0.66 per share in Q1 2014 |
| Cash used in operating activities | $5.81 million | $2.49 million in Q1 2014 |
| Cash and cash equivalents | $19.28 million | $6.71 million at December 31, 2014 |
| Current assets / current liabilities | $19.92 million / $3.61 million | $7.41 million / $9.49 million at December 31, 2014 |
| Notes payable | $189,758 | $283,552 at December 31, 2014 |
| Derivative liabilities | $1.86 million | $6.71 million at December 31, 2014 |
There is no meaningful gross margin because the company reported no revenue. Cash provided by financing was $18.39 million, primarily from a February public offering that generated approximately $18.5 million net proceeds. Management said existing cash was expected to fund operations for the next 12 months. The filing also cites an estimated $9.6 million of funding needs through the end of 2015. The company had an accumulated deficit of $94.28 million.
Material changes and notable items
- R&D expense rose approximately $2.46 million year over year, largely due to increased Iomab-B manufacturing costs and payroll; Actimab-A multicenter trial costs declined approximately $0.2 million.
- G&A expense increased approximately $1.26 million, reflecting higher payroll, stock-based compensation, and consulting fees. Total stock-based compensation was $2.91 million.
- Net loss improved substantially from Q1 2014, principally because the company recorded a $4.80 million gain from revaluing warrant derivative liabilities, versus a $12.56 million loss in Q1 2014. This fair-value gain was not an operating cash inflow; the liability is Level 3 and valuation-sensitive.
- Operating cash use increased from $2.49 million to $5.81 million. The company reported no investing cash outflow in Q1 2015.
- The February offering issued 4,444,444 common shares and warrants for 3,333,333 shares, exercisable for four years at $6.50 per share. Outstanding common shares were 35,705,313 at March 31 and 35,845,856 at May 8, 2015.
Business outlook, risks, and contingencies
- Actinium was pursuing Actimab-A and Iomab-B. Management estimated approximately $7 million of direct costs to complete the two parts of the ongoing Actimab-A Phase 1/2 trial. It intended to ask the FDA in 2015 to proceed with a pivotal Iomab-B trial, estimated to cost $25–30 million through anticipated completion in 2017.
- Management expected R&D and G&A spending to increase. The company’s stated strategy was to advance candidates and seek commercial partners; no partnership or recurring revenue source was in place.
- Material development risks include clinical-trial failure or delay, regulatory approval uncertainty, patient enrollment and safety, reliance on contract manufacturers and research partners, and the need for additional capital and potential dilution. The filing notes prolonged bone-marrow suppression at the highest Actimab-A dose tested, leading to dose reductions.
- Actinium relies on Oak Ridge National Laboratory for Ac-225; its supply contract ran through the end of 2015 and required renewal. The company disclosed limited isotope availability and no guarantee of renewal. Iomab-B was not patent protected, and the company highlighted patent-expiry and licensing concerns for Actimab-A.
- Commitments include approximately $2.1 million remaining under the Goodwin manufacturing agreement and estimated Iomab-B trial development costs. The FHCRC trial development estimate was $13.2–23.5 million, depending on FDA-required design. Conditional license milestones and royalties may also be payable if specified development, approval, or sales events occur.
- MSKCC, a related party and company shareholder, was owed $282,912 for maintenance, clinical-trial, and patent costs. No legal proceedings were reported. Management concluded disclosure controls were effective as of March 31, 2015; no material control changes were reported.
- Subsequent to quarter-end, the CEO agreement provided for specified payments, a lock-up on 25,000 shares, cancellation of 68,000 unvested restricted shares, and milestone-based options for 82,128 shares.
Key facts for investors to verify
- Whether the $19.28 million cash balance and management’s 12-month runway assessment remain adequate against the company’s reported burn rate and planned trial spending.
- The timing, design, funding, and FDA pathway for the proposed Iomab-B pivotal trial, and progress and safety findings for Actimab-A.
- Renewal and adequacy of Ac-225 supply, and progress on manufacturing capacity and remaining contract obligations.
- The impact of outstanding options and warrants, the February offering, and any future equity financing on dilution; also monitor noncash warrant remeasurement effects on reported earnings.
- Progress on licensing and intellectual-property risks, including Iomab-B’s lack of patent protection and the terms of the AbbVie license.